

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	08/444,791
	Filing Date	May 19, 1995
	First Named Inventor	Brockhaus
	Art Unit	1644
	Examiner Name	Ronald B. Schwadron
	Attorney Docket Number	A947-US-DIV4/01017/40451C

U.S. PATENTS

Examiner Initial	Cite No	Patent Number	Kind Code	Issue Date	Name of Patentee or Applicant of cited Document
	A1				
	A2				

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial	Cite No	Publication Number	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document
	B1				
	B2				

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	English Translation attached YES NO
	C1	0 394 827	EP	A1	October 31, 1990	F. Hoffmann-La Roche AG	
	C2						
	C3						
	C4						
	C5						

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.
	D15	Declaration of Taruna Arora under 37 C.F.R. § 1.132 plus Exhibits A-D dated December 16, 2010, filed in sister case U.S. Appln. 08/444,790 (which was filed on May 19, 1995, inventors M. Brockhaus, Z. Dembic, R. Gentz, W. Lesslauer, H. Loetscher, E. Schlaeger, hereinafter "U.S. Appln. 08/444,790")
	D16	Examiner's Answer dated March 24, 2009 from the appeal of U.S. Appln. 08/444,790 before the Board of Patent Appeals and Interferences
	D17	Decision on Appeal, Board of Patent Appeals and Interferences, Appeal No. 2009-014889, Application No. 08/444,790, dated November 22, 2010

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	08/444,791
	Filing Date	May 19, 1995
	First Named Inventor	Brockhaus
	Art Unit	1644
	Examiner Name	Ronald B. Schwadron
	Attorney Docket Number	A947-US-DIV4/01017/40451C

D18	Letter to the European Patent Office regarding the Third Auxiliary Request in the appeal of European Patent Appln. 90906924.7-2118 (issued as European Patent No. 0 471 701, filed May 4, 1990, inventors H. LeMaire, H. Hillen, A. Moeller, L. Daum, T. Doerper, T. Subkowski) from G. Schweiger of Reitstötter, Kinzebach & Partner
D19	Notice of Opposition dated April 2, 2003 to European Patent 0 939 121 (which is related to U.S. Application 08/444,791, filed August 31, 1990, inventors M. Brockhaus, Z. Dembic, R. Gentz, W. Lesslauer, H. Loetscher, E. Schlaeger, hereinafter "European Patent 0 939 121") submitted to the European Patent Office by Gérard Dossmann of Bureau Casalonga & Josse
D20	Statement in Support of Opposition to European Patent 0 939 121 dated December 30, 2003, submitted to the European Patent Office by Gérard Dossmann of Bureau Casalonga & Josse
D21	Patentee's response to notice of opposition to European Patent 0 939 121 dated August 3, 2004 submitted to the European Patent Office by Dr. G. Keller of Lederer & Keller
D22	Opponents Answer dated November 3, 2004 to Patentee's response in the opposition of European Patent 0 939 121 submitted to the European Patent Office by Gérard Dossmann of Bureau Casalonga & Josse
D23	Response to the Communication of November 15, 2004 dated July 22, 2005 in the opposition of European Patent 0 939 121 submitted to the European Patent Office by A. v. Menges of Uexküll & Stolberg
D24	Opponent's Observations under Rule 71a EPC dated Sept. 22, 2006 in the opposition of European Patent 0 939 121 submitted to the European Patent Office by Gérard Dossmann of Bureau Casalonga & Josse
D25	Comments of the patentee in preparation for oral hearing and in response to the preliminary opinion in the opposition of European Patent 0 939 121 dated September 22, 2006, submitted to the European Patent Office by A. v. Menges and M. Weber-Quitzau of Uexküll & Stolberg
D26	ARORA et al., "Differences in Binding and Effector Functions Between Classes of TNF Antagonists," Cytokine 45: 124-131 (2009)
D27	ARRUFFO et al., "CD44 Is the Principal Cell Surface Receptor for Hyaluronate," Cell 61: 1303-1313 (1990)
D28	BRENNAN et al., "Inhibitory Effect of TNFa Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis," Lancet 2(8657): 244-247 (1989)
D29	CHAN et al., "A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling," Science 288: 2351-2354 (2000)
D30	ENGELMANN et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," J. Biol. Chem. 265(3): 1531-36 (1990)
D31	MITOMA et al., "Mechanisms for Cytotoxic Effects of Anti-Tumor Necrosis Factor Agents on Transmembrane Tumor Necrosis Factor α -Expressing Cells," Arthr. & Rheum. 58(5): 1248-1257 (2008)
D32	NOVICK et al., "Soluble Cytokine Receptors Are Present in Normal Human Urine," J. Exp. Med., 170: 1409-1414 (1989)
D33	SHALABY et al., "The Involvement of Human Tumor Necrosis Factors- α and - β in the Mixed Lymphocyte Reaction, J. Immunol. 141: 499-503 (1988)

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	08/444,791
		Filing Date	May 19, 1995
		First Named Inventor	Brockhaus
		Art Unit	1644
		Examiner Name	Ronald B. Schwadron
		Attorney Docket Number	A947-US-DIV4/01017/40451C

	D34	SMITH and BAGLIONI, "Multimeric Structure of the Tumor Necrosis Factor Receptor of HeLa Cells," <i>J. Biol. Chem.</i> 264: 14646-14652 (1989)
	D35	STRAND et al., "Biologic Therapies in Rheumatology: Lessons Learned, Future Directions," <i>Nature Rev.</i> 6: 75-92 (2007)
	D36	STRANGFELD ET AL., "Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Anti-TNF- α Agents," <i>JAMA</i> 301(7): 737-744 (2009)
	D37	WALLIS et al., "Reactivation of Latent Granulomatous Infections by Infliximab," <i>Clin. Inf. Dis.</i> 41(Suppl 2): S1-S5 (2005)
	D38	WALLIS et al., "Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists," <i>Clin. Inf. Dis.</i> 38: 1261-1265 (2004)
	D39	WATSON et al., "A Homing Receptor – IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venules," <i>J. Cell Biol.</i> 110: 2221-2229 (1990)
	D40	WINZOR et al., "Evaluation of Equilibrium Constants from Precipitin Curves: Interaction of α -Crystallin with an Elicited Monoclonal Antibody," <i>Arch. Biochem. Biophys.</i> 268(1): 221-226 (1989)
	D41	FURST et al. "Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action may Explain Differences in the Risk for Developing Granulomatous Infection," <i>Semin. Arthritis Rheum.</i> 36(3):159-67. (2006)
	D42	United States Adopted Names (USAN) Council Report, <i>Clin. Pharm. & Ther.</i> , vol. 66, no. 2, August 1999, page 209

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	